<DOC>
	<DOCNO>NCT00593879</DOCNO>
	<brief_summary>Depressed patient receive 6 week citaloprma ( 20-40mg ) therapy . Subjects inadequate response ( partial non-responder ) randomize receive either mecamylamine ( 5-10mg ) placebo add citalopram 8 week .</brief_summary>
	<brief_title>Flexible Dose Titration Add-on Study Treat Major Depressive Disorder</brief_title>
	<detailed_description>This double blind , randomize , placebo control , parallel group , flexible dose titration , add-on study . Male female subject age 18-70 year suffer Major Depressive Disorder accord DSM-IV , HAMD-17 score great 21 CGI-Severity Illness score great equal 4 , start open label citalopram treatment . The dose citalopram may increase form 20mg 40mg six week period , depend investigator assessment tolerability efficacy . At end treatment , subject HAMD-17 score great equal 14 CGI-Severity Illness score great equal 4 consider partial non-responders enter double blind phase study . Subjects randomize either mecamylamine placebo 8 week . Citalopram medication remain constant mecamylamine ( placebo ) increase 5.0 7.5 10.0mg base investigator assessment tolerability efficacy . Plasma sample citalopram assay collect start end double blind phase exclude mecamylamine effect due drug : drug interaction . Approximately 500 subject enter open-label phase study approximately 160 double blind phase . The study conduct India USA .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mecamylamine</mesh_term>
	<criteria>( A ) Open Phase Male female subject age 1870 year . Diagnosis major depressive disorder ( MDD ) accord DSMIV confirm via MINI diagnostic scale . Able give write informed consent . HAMD17 score great 21 . CGISeverity Illness score great equal 4 . No clinically significant abnormality physical examination , vital sign , ECG laboratory test ( biochemical , hematological , urinary ) screening . Women child bear potential negative urine pregnancy test willing use acceptable method contraception . ( B ) Double Blind Phase : Subjects still meet DSMIV criterion MDD . Subjects continue meet inclusion exclusion criterion . HAMD17 score great equal 14 . CGI severity illness score great equal 4 . Women child bear potential negative urine pregnancy test willing use acceptable method contraception . Aged 18 year 70 year . Failure meet DSM IV criterion MDD . HAMD17 le equal 21 ( openlabel phase ) . CGI Severity Illness score less 4 . Clinically significant change physical examination , vital sign , ECG laboratory test screen . Any co morbid psychiatric illness confirm MINI diagnostic scale , especially bipolar disorder , schizophrenia dementia . Subjects significant suicidal risk upon clinical assessment . Subjects treatment resistant depression i.e . failed adequate course ( daily dose duration treatment ) one antidepressant . History alcohol drug abuse last 6 month . History seizures seizure disorder . Seropositive HIV hepatitis B ( antibody antigen ) . Any severe progressive uncontrolled medical condition . For controlled medical condition , medication unchanged 2 month precede screening , else patient exclude . Subjects Glaucoma , Kidney Disease Heart Disease . Known hypersensitivity mecamylamine . Women child bear potential take adequate contraception woman breastfeed . Other investigational drug previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
	<keyword>Mecamylamine</keyword>
	<keyword>Add-on Therapy</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>